PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
News|Articles|November 26, 2015
KTN Launches UK Medicines Manufacturing Landscape Portal
Author(s)Pharmaceutical Technology Editors
The portal is an interactive tool that pulls together the innovation landscape, company base, and manufacturing sites for the entire medicines sector in the UK.
Advertisement
The Knowledge Transfer Network (KTN), the United Kingdom’s innovation network,
KTN’s Medicines Manufacturing Landscape portal is an interactive tool that pulls together the innovation landscape, company base, and manufacturing sites for the entire medicines sector in the UK. The platform was developed by KTN on behalf of the Medicines Manufacturing Industry Partnership (MMIP) to address confusion about medicines manufacturing activities in the UK.
The MMIP was jointly established by the Association of the British Pharmaceutical Industry (ABPI) and the BioIndustry Association (BIA) and includes partners such as Actavis (Allergan plc), AstraZeneca, Eisai, Fujifilm Diosynth Biotechnologies, GlaxoSmithKline, KTN, ReNeuron, and Pfizer. This partnership was formed to strengthen collaboration between the industry and the government in making the UK an attractive and innovation-driven country for medicines manufacturing.
Source:
Advertisement
Related to this article
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
AI can turn medical device risk management into a continuous signal.
Sanofi will transfer 20 mature medicines and three manufacturing sites to Cheplapharm for a 26.4% equity stake, closing by Q3 2027.
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
Christy Owings, Thermo Fisher, on why early supply chain partnership and site visits prevent costly eCOA and clinical trial delays.
This article explores the historical use of silicone oil in the performance of primary drug product packaging; design of experiment test results for selection of the cleaning agent and CCPs; assessment of visible residue limits and Fourier-transform infrared spectroscopy surface analysis; and setting health-based exposure limits for silicone oil using a non-uniform distribution model, and a previously published permitted daily exposure.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Driving Quality Culture to Manage Risk: Lessons from an FDA Inspection Response
2
Mature Medicines Divestment Signals Shift in Manufacturing Strategy
3
FDA's IND Pilot Puts CMC Review First
4
Successful Internal Audit Planning and Execution
5